LX1
LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide , and the combination with Enzalutamide (HY-70002) further inhibits tumor growth[1].
Product Specifications
CAS Number
2647877-84-5
UNSPSC
12352005
Target
Aldose Reductase; Androgen Receptor
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lx1.html
Purity
99.13
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=C(O)C=CC(CC3=CC=CC=C3)=C2
Molecular Formula
C22H15F6NO2
Molecular Weight
439.35
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HADHAP sgRNA CRISPR Lentivector (Human) (Target 2)
